World Business

DUBLIN, Ireland Shares in Ireland’s major biopharmaceutical company, Elan Corp. PLC, suffered their worst fall in more than three years Wednesday after a drug being developed to draw the sword Alzheimer’s Disease reported disappointing results.

Watch original video:

Elan shares plummeted over 27 percent to euro14.90 ($23.25) in morning trade on the Irish Stock Exchange, forcing the wider exponent into negative territory.

The drop followed Tuesday night’s unveiling of abounding phase-two results of bapineuzumab. Elan and U.S. biopharmaceutical giant Wyeth get been developing the drug in hopes it could become the in the beginning to reverse the brain-ravaging effects of Alzheimer’s, what one. afflicts more than 25 million the multitude worldwide.

Last month the companies said the medicine showed signs of working, but the full trial results indicated that the drug was inefficacious. in treating people who have the ApoE4 gene most commonly found in Alzheimer’s victims. Among those who lacked the gene, the drug did be obvious to slow down, admitting that not reverse, mental deterioration.

The detailed findings, presented at the International Conference on Alzheimer’s Disease in Chicago, also linked practice of the drug to a wide range of potential side movables, including brain swelling, paranoia, anxiety, vomiting and extreme blood pressure.

Experts appeared divided on the results, but investors dumped Elan and Wyeth shares because the results were much in a less degree upbeat than the companies’ advance characterizations. Elan and Wyeth are even now pursuing a final-phase trial involving 4,000 Alzheimer’s victims.

Shares in Wyeth fell more than 7 percent Wednesday on Germany’s DAX characteristic in Frankfurt.

Wyeth is much less dependent on the performance of bapineuzumab than its smaller Irish associate, that is banking on delivering any Alzheimer’s breakthrough for its future growth.

Elan currently is pursuing seven trials of potential drugs for Alzheimer’s and two for multiple sclerosis, an incurable disease that attacks the nervous system.

The Dublin-based company nearly went bankrupt in 2002 following the failure of previous Alzheimer’s research and the discovery of loss-hiding accounting practices, and has battled red ink as antidote to the past six years.

But the company said last week it is within a year of returning to advancement acknowledgments to the success of Tysabri, an MS mix with drugs developed in affinity with U.S. drugmaker Biogen Idec Inc. and approved for sale in the U.S. and European markets in mid-2006.

The last age Elan’s shares fell in the way that sharply was in March 2005, after Tysabri was linked to three cases of a rare, deadly brain disease called PML and was withdrawn suddenly from U.S. sale. The drug returned to the market after extensive screening of Tysabri users raise no in addition PML cases.